Kyverna Therapeutics, Inc. (KYTX)

Market Cap	149.97M
Revenue (ttm)	n/a
Net Income (ttm)	-158.70M
Shares Out	43.22M
EPS (ttm)	-3.67
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	514,456
Open	3.040
Previous Close	3.020
Day's Range	2.955 - 3.520
52-Week Range	1.780 - 8.780
Beta	n/a
Analysts	Strong Buy
Price Target	15.50 (+346.69%)
Earnings Date	Aug 12, 2025

About KYTX

Kyverna Therapeutics, Inc., clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. The company’s lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome and myasthenia gravis that is in phase 2 clinical trial; and for lupus nephritis. It is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing, as well as KYV-201, an allogeneic CD19 CAR T-cell product candida...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 8, 2024
• Employees: 112
• Stock Exchange: NASDAQ
• Ticker Symbol: KYTX
• Website: https://kyvernatx.com

Analyst Forecast

According to 4 analysts, the average rating for KYTX stock is "Strong Buy." The 12-month stock price target is $15.5, which is an increase of 346.69% from the latest price.

Price Target

$15.5

(346.69% upside)

Analyst Consensus: Strong Buy